Zoetis Expands U.S. Manufacturing Footprint

As the world’s leading animal health company with headquarters in the U.S., Zoetis has long-believed in the value of U.S.-based innovation and manufacturing. Since the 2017 tax reform, Zoetis has invested $1.7 billion in its U.S. manufacturing sites and plans to invest an additional $1.3 billion through 2031 across its nine sites in seven states. The company’s investments in these areas have created jobs – more than 2,700 colleagues are employed at Zoetis’ nine U.S. manufacturing sites in seven states – that help reliably supply essential animal health products to care for pets and livestock in the U.S. and around the world, with the company growing its revenue from $5.3 billion in 2017 to $9.3 billion in 2024. 

With 99% of its intellectual property rooted in the U.S. and 60% of the company’s global manufacturing taking place in the U.S., more than 75% of its U.S. sales in 2025 are expected to be derived from products made on American soil. As a net exporter, Zoetis is not only meeting the needs of veterinarians, livestock producers and pet owners in the U.S., but also supplying critical animal health products to more than 100 additional markets.

The company recently made a $590 million investment in a new manufacturing site located in Douglasville, Georgia, near Atlanta. The facility is already 70% complete and expected to be operational by 2029, creating approximately 100 new jobs to continue to meet the demand for innovative monoclonal antibody (mAb) and vaccine products for companion animals.

"Our investment in the new, state-of-the-art Atlanta facility marks a pivotal moment in our journey to advance animal health,” said Kristin Peck, CEO of Zoetis. “By expanding our capabilities here, we’re not only driving innovation but also reaffirming our commitment to meeting the evolving needs of our customers, who count on us for breakthrough solutions that support the health and well-being of pets everywhere.”

Designed to be a premier technology and digital innovation hub, the Atlanta facility will feature advanced manufacturing technologies such as collaborative robots (cobots), virtual reality training, a next-generation Manufacturing Execution System (MES), and a comprehensive manufacturing data fabric. These features are expected to streamline operations, boost productivity and attract top talent. 

In addition to its new site in Georgia, Zoetis has eight other manufacturing sites in six additional states. The company’s two sites in California and one in North Carolina are dedicated to diagnostics and biodevices; its site in Michigan produces pharmaceuticals, and its sites in Illinois, Iowa and Nebraska make vaccines and other biopharma products including mAbs. As Zoetis continues to grow, its investments in U.S. manufacturing underscore its broader commitment to drive innovation, support local communities, and ensure a resilient supply chain for the future needs of animal health.